5. Culturally Competent Care for Substance Users Diagnosed with HIV Disease
Comorbidity of Substance Abuse and HIV Infection, cont.
Injection Drug Use
In the United States, approximately 1 million individuals are active IDUs, in addition to the many others who use noninjection drugs or abuse alcohol. The sharing of syringes and other drug-injection equipment has acted as a significant route of HIV transmission since the beginning of the epidemic. However, injection drug use adds to the transmission of HIV beyond just IDUs themselves, including people who engage in sexual activity with IDUs, children born to women who contracted HIV through sharing needles or having sex with an IDU. Moreover, IDU impairs decision making and increases sexual risk-taking behavior, thereby increasing the risk for acquiring HIV. [NIDA "How does?"]
Racial and ethnic minority populations are disproportionately represented among persons with IDU-related diagnoses of AIDS. In 2000, IDU-associated AIDS accounted for 26% of all AIDS cases among African American and 31% among Hispanic adults and adolescents vs 19% of all cases among white adults/adolescents. [NHSDA 2003]
Standard advice for IDUs includes that sterile injection equipment should always be used; that needles, syringes, and other injection equipment should never be reused; and that using syringes that have been cleaned with bleach or other disinfectants is not as safe as using new syringes. However, IDU treatment is not limited to access to sterile injection equipment and requires a comprehensive approach incorporating several basic principles:
- Ensure collaboration among all providers of services to IDUs, their sex partners, and their children
- Ensure access to and quality of interventions
- Recognize and overcome stigma associated with injection drug use
- Tailor services and programs to the racially, ethnically, and culturally diverse populations of IDUs
Even though substance abuse treatment is a vital part of accessing and successfully remaining in HIV care, too few substance abuse treatment programs are available to meet the need. The introduction of the opioid replacement drug buprenorphine, which may be given in a primary care setting, may improve access to substance use treatment. However, administration of buprenorphine requires special training, which may not be readily available in all settings.